Efficacy and Safety of the Tetravalent Meningococcal Vaccine
Keywords:
tetravalente, meningocócica, vacuna, eficacia, seguridadAbstract
Introduction: Invasive meningococcal disease (IMD) is a severe acute bacterial infection, and in the vast majority of cases is caused by five serogroups of Neisseriameningitidis (A, B, C, W, Y). The burden of disease and high mortality rates highlight the need for prevention through effective and safe active immunization.
Objective: Describe the efficacy and safety of the quadrivalent meningococcal vaccine.
Methods: This is a systematic review study. The proposals to improve the publication of PRISMAScR systematic reviews were followed. All articles available in English, published in peer-reviewed academic journals, and published between 2017 and 2022 were included. Articles describing the efficacy and safety of vaccines other than quadrivalent meningococcal vaccines were excluded.
Results: After content analysis of the 8 included articles, four ACWY meningococcal vaccine themes were identified: infants and toddlers, children 2-10 years, adolescents, and adults, all ages. Regarding safety, regardless of age range, we highlight injection site pain as one of the most common adverse effect registry reports. In relation to efficacy, the articles analyzed focus on the persistence of antibodies over time in relation to doses/age.
Conclusions: There is a clear need to develop effective and safe standardized tools in the meningococcal vaccine, since at the international level there are different vaccine strategies, presentations and immune responses.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Francisco Miguel Escandell Rico, Lucia Pérez Fernández
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aviso de derechos de autor/a
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
